Veradermics, Incorporated (MANE) Financial Statements
Free cash flow over the same period: -$78.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MANEVeradermics, IncorporatedFollow MANE — free
—
Price chart with a free account
- Market cap
- 5.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Research & development | 23.3 | 62.1 | — | |
| Operating income | -26.8 | -72.3 | -102.8 | |
| Pre-tax income | -26.5 | -70.0 | -92.7 | |
| Income tax | 0.0 | 0.0 | 0.0 | |
| Net income | -26.5 | -70.0 | -92.7 | |
| Diluted EPS ($) | -37.05 | -111.91 | — | |
| Diluted shares (mn) | 0.7 | 0.7 | — |
USD millions · SEC XBRL
Veradermics, Incorporated — questions
- What is Veradermics, Incorporated's net income?
- -$92.7M over the twelve months to 2026-06-30.
- What is Veradermics, Incorporated's free cash flow?
- -$78.3M over the twelve months to 2026-06-30.
Every figure on this page comes from Veradermics, Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.